Core Viewpoint - Donghai Securities report indicates that Yifeng Pharmacy achieved a net profit attributable to shareholders of 1.225 billion yuan in the first three quarters of 2025, representing a year-on-year increase of 10.27% [1] Financial Performance - In Q3 alone, the company reported a net profit attributable to shareholders of 345 million yuan, which is a year-on-year increase of 10.14% but a quarter-on-quarter decrease of 19.98% [1] Operational Efficiency - The company has demonstrated robust profit growth through cost reduction, efficiency enhancement, and optimization of its operational structure, showcasing its excellent management capabilities and operational resilience [1] Business Strategy - The new retail business continues to grow significantly, and the initial results of the non-pharmaceutical innovation strategy are becoming evident [1] - The company plans to launch a transformation of non-pharmaceutical innovative stores in 2025, with nationwide promotion expected in 2026, which is anticipated to open new growth opportunities [1] Market Position - Yifeng Pharmacy is recognized as a leading retail pharmacy with stable operations and unique refined management capabilities, while its diversified business approach is expected to provide long-term development potential [1] Investment Rating - The report maintains a "Buy" rating for the company [1]